ArticlebioRxiv : the preprint server for biology2025
Brain Multi-Omic Subtypes of Neuroticism reveal molecular signatures linked to Alzheimer's Disease.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Importance: Molecular mechanisms linking neuroticism with Alzheimer's disease traits are unknown. Objective: To identify molecular subtypes of neuroticism and examine their association with ADRD traits. Design: Three ongoing cohort studies were used; Religious Orders Study (ROS), Rush Memory and Aging Project (MAP) and Minority Aging Research Study (MARS), that began enrollment in 1994, 1997, and 2004, respectively. Setting: Older priests, nuns, and brothers from across the U.S. (ROS), older adults (MAP) and older African-American adults (MARS) from across the greater Chicago metropolitan area. Participants: 1,028 decedents with multi-omic data from the dorsolateral prefrontal cortex (DLPFC), the anterior cingulate cortex (AC), and the posterior cingulate gyrus (PCG). Exposures: Eight layers of omics (DNA methylation and histone acetylation from DLPFC; RNA seq from AC, DLPFC, and PCG, single-nucleus RNA, TMT proteomics and metabolomics from DLPFC) and Neuroticism using the 12-item version from the NEO Five-Factor Inventory. Main outcomes and measures: Person-specific multi-omic molecular pseudotime representing molecular progression from low to high phenotypic expression of neuroticism, and three multi-omic brain molecular subtypes of neuroticism which represent distinct omic pathways from no/low neuroticism to high neuroticism that differ by their omic constituents. Participants are exclusively assigned to the subtype which aligns mostly with their multi-omic profile. Results: The top drivers of subtype differentiation were transcriptomic alterations across three brain regions (DLPFC, AC, PCG) which extensively and differentially characterized the subtypes. The subtypes were also differentially associated with AD pathology, temporal lobe atrophy, and AD dementia, with subtype N Conclusions and Relevance: Neuroticism may be driven by three distinct molecular subtypes, with subtype N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.